Solomon Moshkevich Sells 80,000 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 80,000 shares of the company’s stock in a transaction on Tuesday, April 16th. The stock was sold at an average price of $90.82, for a total transaction of $7,265,600.00. Following the sale, the insider now directly owns 117,560 shares of the company’s stock, valued at $10,676,799.20. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Natera Trading Up 0.0 %

Shares of Natera stock opened at $90.33 on Thursday. The company has a current ratio of 4.10, a quick ratio of 3.96 and a debt-to-equity ratio of 0.37. The company has a 50-day simple moving average of $85.39 and a 200 day simple moving average of $65.41. Natera, Inc. has a 12-month low of $36.90 and a 12-month high of $98.82.

Natera (NASDAQ:NTRA) last announced its earnings results on Wednesday, February 28th. The medical research company reported ($0.64) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.09. The business had revenue of $311.11 million during the quarter, compared to analysts’ expectations of $300.38 million. Natera had a negative net margin of 40.16% and a negative return on equity of 62.19%. Analysts predict that Natera, Inc. will post -2.35 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Natera

A number of hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. increased its position in shares of Natera by 5.7% during the 4th quarter. Vanguard Group Inc. now owns 10,971,895 shares of the medical research company’s stock worth $687,280,000 after purchasing an additional 588,147 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in Natera by 0.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 7,556,792 shares of the medical research company’s stock worth $334,388,000 after acquiring an additional 67,102 shares during the last quarter. State Street Corp grew its holdings in Natera by 20.4% during the 2nd quarter. State Street Corp now owns 3,409,372 shares of the medical research company’s stock worth $120,828,000 after acquiring an additional 577,106 shares during the last quarter. Alliancebernstein L.P. grew its holdings in Natera by 55.5% during the 2nd quarter. Alliancebernstein L.P. now owns 3,072,466 shares of the medical research company’s stock worth $149,506,000 after acquiring an additional 1,096,964 shares during the last quarter. Finally, Kynam Capital Management LP grew its holdings in Natera by 3.6% during the 3rd quarter. Kynam Capital Management LP now owns 3,003,668 shares of the medical research company’s stock worth $132,912,000 after acquiring an additional 103,668 shares during the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Wall Street Analysts Forecast Growth

NTRA has been the subject of several recent analyst reports. Craig Hallum initiated coverage on shares of Natera in a report on Monday, April 8th. They set a “buy” rating and a $117.00 price objective for the company. Piper Sandler upped their target price on shares of Natera from $70.00 to $110.00 and gave the company an “overweight” rating in a research note on Wednesday, March 6th. Sanford C. Bernstein upgraded shares of Natera from a “market perform” rating to an “outperform” rating and set a $120.00 target price for the company in a research note on Friday, April 5th. BTIG Research upped their target price on shares of Natera from $75.00 to $85.00 and gave the company a “buy” rating in a research note on Friday, December 29th. Finally, Stephens reiterated an “overweight” rating and set a $78.00 target price on shares of Natera in a research note on Tuesday, January 30th. One equities research analyst has rated the stock with a sell rating and fourteen have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $86.40.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.